Exelixis, Inc. EXEL
Set alert
As of Nov 2, 10:06 AM ET
- YTD
- +60.05%
- 1 year
- +81.41%
- Open
- 69.53
- Prev close
- 69.39
- Mkt cap
- 17.54B
- Vol
- 735.25K
- Avg vol
- 2.38M
- EPS
- 3.34
- P/E
- 21.52
- Div yield
- 0.00%
More statistics
- Low
- 69.16
- High
- 71.98
- Forward P/E
- 16.10
- Beta
- 0.47
- Short ratio
- 11.69
- Inst. own
- 107.42%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 59.07
- 200-d avg
- 50.79
- 1y target
- 55.53
5D chart
Events in this range
- Oct 29, 2026Earnings: 0.94; estimate 0.887; surprise 5.98%
- Oct 30, 2026Rating: Barclays · Equal-Weight → Equal-Weight
- Oct 30, 2026Rating: Truist Securities · Hold → Hold
- Oct 30, 2026Rating: RBC Capital · Sector Perform → Sector Perform
- Oct 30, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Oct 30, 2026Rating: TD Cowen · Buy → Buy
Signals (95)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 10:05 AM | 1 minute ago |
| SMA: Bullish | Nov 2, 9:30 AM | 36 minutes ago |
| SMA: Bullish | Nov 2, 9:30 AM | 36 minutes ago |
| MACD: Buy Signal | Nov 2, 9:30 AM | 36 minutes ago |
| RSI: Oversold | Oct 30, 3:50 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:20 PM | 2 days ago |
| RSI: Oversold | Oct 30, 2:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:25 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 10:35 AM | 3 days ago |
| RSI: Overbought | Oct 30, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:20 PM | 3 days ago |
| RSI: Oversold | Oct 29, 12:10 PM | 3 days ago |
| RSI: Oversold | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:50 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:00 PM | 4 days ago |
| RSI: Oversold | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:35 AM | 4 days ago |
| RSI: Overbought | Oct 28, 11:10 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 6 days ago |
News
1 hour ago benzinga.com
Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter
Regeneron, AstraZeneca and Exelixis show overbought RSI readings after strong gains, warning momentum-focused investors of potential pullbacks.
-
3 hours ago benzinga.com
HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $78
HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $56 to $78.
-
2 days ago benzinga.com
TD Cowen Maintains Buy on Exelixis, Raises Price Target to $76
TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $55 to $76.
-
2 days ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $60
Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $53 to $60.
2 days ago zacks.com
EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
Exelixis tops Q3 2026 earnings and revenue estimates as Cabometyx sales grow, share repurchases accelerate and its zanzalintinib pipeline advances.
-
2 days ago benzinga.com
RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $58
RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and raises the price target from $51 to $58.
-
2 days ago benzinga.com
Truist Securities Maintains Hold on Exelixis, Raises Price Target to $60
Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price target from $54 to $60.
-
3 days ago benzinga.com
Barclays Maintains Equal-Weight on Exelixis, Raises Price Target to $54
Barclays analyst Etzer Darout maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $49 to $54.
3 days ago benzinga.com
AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday
U.S. stocks fell Friday, but AutoNation jumped 8% after beating Q3 estimates; OneSpan, Grid Dynamics and others posted double-digit gains.
3 days ago seekingalpha.com
Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript
Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript
3 days ago marketbeat.com
What Exelixis (EXEL) Said on Its Q3 Earnings Call
Exelixis NASDAQ: EXEL reported third-quarter 2026 revenue of approximately $659 million, supported by continued growth in its cabozantinib franchise and progress toward a potential launch of…
3 days ago zacks.com
Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
3 days ago zacks.com
Exelixis (EXEL) Surpasses Q3 Earnings and Revenue Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.78 per share a year ago.
3 days ago benzinga.com
Exelixis Q3 2026 Earnings Call Transcript
Exelixis (NASDAQ:EXEL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time…
-
3 days ago benzinga.com
Exelixis Affirms FY2026 Sales Guidance of $2.500B-$2.550B vs $2.549B Est
Exelixis (NASDAQ:EXEL) affirms FY2026 sales outlook from $2.500 billion-$2.550 billion to $2.500 billion-$2.550 billion vs $2.549 billion estimate.
-
3 days ago benzinga.com
Exelixis Q3 Adj. EPS $0.94 Beats $0.80 Estimate, Sales $658.696M Beat $646.510M Estimate
Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.80 by 17.5 percent. This is a 20.51 percent increase over earnings of $0.78 per…
3 days ago businesswire.com
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate…
6 days ago seekingalpha.com
Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update
The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital,…
6 days ago marketbeat.com
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Bristol Myers Squibb TodayBMYBristol Myers Squibb$61.20 -0.28 (-0.45%) As of 01:50 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$42.52▼$68.64Dividend…
1 week ago fool.com
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
Regulators in the U.S. extended the review period for Exelixis' request to approve a new cancer drug. However, the company's most important medicine is performing well and still has several years of…
1 week ago fxempire.com
Exelixis Rises with Earnings on Tap
Shares of oncology company Exelixis, Inc. (EXEL) are higher by 177% since 2017.
1 week ago zacks.com
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 week ago benzinga.com
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
2 weeks ago benzinga.com
Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $65
Citizens analyst Silvan Turkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and raises the price target from $55 to $65.
2 weeks ago zacks.com
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2 weeks ago zacks.com
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2 weeks ago gurufocus.com
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a
2 weeks ago prnewswire.com
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL) breached their…
2 weeks ago defenseworld.net
Exelixis (NASDAQ:EXEL) Hits New 1-Year High – Here’s What Happened
Shares of Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) reached a new 52-week high during mid-day trading on Monday. The stock traded as high as $61.66 and last traded at $60.9990, with a volume of…
-
3 weeks ago benzinga.com
RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $51
RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and raises the price target from $45 to $51.
-
3 weeks ago benzinga.com
RBC Capital Maintains Sector Perform on Exelixis, Lowers Price Target to $45
RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and lowers the price target from $46 to $45.
3 weeks ago zacks.com
Here's Why Exelixis (EXEL) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
1 month ago fxempire.com
Exelixis Shares Rising on CABOMETYX Revenue
Big Money pushes Exelixis, Inc. (EXEL) shares higher by 149% since 2017.
1 month ago zacks.com
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
1 month ago zacks.com
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.
1 month ago benzinga.com
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.
-
1 month ago benzinga.com
Exelixis Announces Three-Month FDA Review Period Extension For Its Zanzalintinib New Drug Application In Combination With Atezolizumab For The Treatment Of Metastatic Colorectal Cancer
In response to an FDA information request, Exelixis had submitted updated safety and efficacy data, which the FDA has deemed a major amendment. The updated Prescription Drug User Fee Act action date…
-
2 months ago benzinga.com
Exelixis Announces Appellate Court Affirms Key Part Of 2024 Judgement Of U.S. District Court In Favor Of Co. Against MSN Laboratories; Appellate Court Upholds District Court Decision That Three Patents Are Not Invalid Covering Crystalline Malate Salt Of Cabozantinib
Exelixis, Inc. (NASDAQ:EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court…
-
2 months ago benzinga.com
BMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces Price Target of $54
BMO Capital analyst David Lebowitz initiates coverage on Exelixis (NASDAQ:EXEL) with a Market Perform rating and announces Price Target of $54.
-
2 months ago benzinga.com
Truist Securities Maintains Hold on Exelixis, Lowers Price Target to $52
Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and lowers the price target from $56 to $52.
-
2 months ago benzinga.com
Stifel Maintains Hold on Exelixis, Raises Price Target to $51
Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price target from $47 to $51.
-
2 months ago benzinga.com
Exelixis Lowers FY2026 Sales Guidance from $2.525B-$2.625B to $2.500B-$2.550B vs $2.595B Est
Exelixis (NASDAQ:EXEL) lowers FY2026 sales outlook from $2.525 billion-$2.625 billion to $2.500 billion-$2.550 billion vs $2.595 billion estimate.
-
2 months ago benzinga.com
Exelixis Q2 Adj. EPS $0.91 Beats $0.79 Estimate, Sales $628.700M Miss $635.951M Estimate
Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.79 by 15.19 percent. This is a 21.33 percent increase over earnings of $0.75 per…
-
3 months ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $53
Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $50 to $53.
-
3 months ago benzinga.com
Barclays Maintains Equal-Weight on Exelixis, Raises Price Target to $49
Barclays analyst Etzer Darout maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $45 to $49.
-
3 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Exelixis, Raises Price Target to $49
Wells Fargo analyst Eva Fortea Verdejo maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $40 to $49.
-
3 months ago benzinga.com
RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $46
RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and raises the price target from $43 to $46.
-
3 months ago benzinga.com
Truist Securities Maintains Hold on Exelixis, Raises Price Target to $56
Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price target from $54 to $56.
-
4 months ago benzinga.com
UBS Maintains Neutral on Exelixis, Raises Price Target to $52
UBS analyst Ashwani Verma maintains Exelixis (NASDAQ:EXEL) with a Neutral and raises the price target from $43 to $52.
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $56 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ:EXEL) with a Buy and maintains $56 price target.